139 related articles for article (PubMed ID: 3815729)
1. Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer.
Erlichman C; Soldin SJ; Thiessen JJ; Sturgeon JF; Fine S
Cancer Chemother Pharmacol; 1987; 19(1):75-9. PubMed ID: 3815729
[TBL] [Abstract][Full Text] [Related]
2. Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma.
Erlichman C; Soldin SJ; Hardy RW; Thiessen JJ; Sturgeon JF; Fine S; Baskerville T
Arzneimittelforschung; 1988 Jun; 38(6):839-42. PubMed ID: 3178926
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin disposition in children and adolescents with cancer.
Crom WR; Evans WE; Pratt CB; Senzer N; Denison M; Green AA; Hayes FA; Yee GC
Cancer Chemother Pharmacol; 1981; 6(1):95-9. PubMed ID: 7196807
[TBL] [Abstract][Full Text] [Related]
4. Disposition of unchanged cisplatin in patients with ovarian cancer.
Reece PA; Stafford I; Davy M; Freeman S
Clin Pharmacol Ther; 1987 Sep; 42(3):320-5. PubMed ID: 3621787
[TBL] [Abstract][Full Text] [Related]
5. Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.
Leone R; Fracasso ME; Soresi E; Cimino G; Tedeschi M; Castoldi D; Monzani V; Colombi L; Usari T; Bernareggi A
Cancer Chemother Pharmacol; 1992; 29(5):385-90. PubMed ID: 1312907
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of cisplatin in long-term hemodialysis treatment].
Sturn W; Sanwald R; Ehninger G
Dtsch Med Wochenschr; 1989 Mar; 114(9):337-9. PubMed ID: 2920679
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of intraperitoneal cisplatin.
Lopez JA; Krikorian JG; Reich SD; Smyth RD; Lee FH; Issell BF
Gynecol Oncol; 1985 Jan; 20(1):1-9. PubMed ID: 4038390
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin and cisplatin excretion into human milk.
Egan PC; Costanza ME; Dodion P; Egorin MJ; Bachur NR
Cancer Treat Rep; 1985 Dec; 69(12):1387-89. PubMed ID: 4075315
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors.
Bonetti A; Franceschi T; Apostoli P; Messori A; Sperotto L; Cetto GL; Molino A; Leone R
Ther Drug Monit; 1995 Feb; 17(1):25-32. PubMed ID: 7725373
[TBL] [Abstract][Full Text] [Related]
10. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin.
Reece PA; Stafford I; Russell J; Gill PG
J Clin Oncol; 1986 Sep; 4(9):1392-8. PubMed ID: 3746376
[TBL] [Abstract][Full Text] [Related]
11. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Passos-Coelho JL; Noe DA; Kennedy MJ; Black KC; Colvin OM; Grochow LB
Cancer Res; 1995 Feb; 55(4):810-6. PubMed ID: 7850794
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma.
Pretorius RG; Hacker NF; Berek JS; Ford LC; Hoeschele JD; Butler TA; Lagasse LD
Cancer Treat Rep; 1983 Dec; 67(12):1085-92. PubMed ID: 6228294
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma].
Han GR; Cai GF
Zhonghua Fu Chan Ke Za Zhi; 1993 Apr; 28(4):224-6, 254. PubMed ID: 8404307
[TBL] [Abstract][Full Text] [Related]
14. Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer.
Reece PA; Stafford I; Davy M; Morris R; Freeman S
Cancer Chemother Pharmacol; 1989; 24(4):256-60. PubMed ID: 2752507
[TBL] [Abstract][Full Text] [Related]
15. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
16. Test dose-guided administration of cisplatin in an anephric patient: a case report.
Ribrag V; Droz JP; Morizet J; Leclercq B; Gouyette A; Chabot GG
Ann Oncol; 1993 Sep; 4(8):679-82. PubMed ID: 8240999
[TBL] [Abstract][Full Text] [Related]
17. Two-cycle cisplatin kinetics in patients with ovarian and mammary cancer.
Leone R; Benoni G; Apostoli P; Bonetti A; Griso C; Fracasso ME
Ther Drug Monit; 1987 Dec; 9(4):374-7. PubMed ID: 3424403
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of platinum in cancer patients treated with cisplatin at different doses.
Fracasso ME; Apostoli P; Benoni G; Bonetti A; Griso C; Leone R
Drugs Exp Clin Res; 1987; 13(6):367-72. PubMed ID: 3652926
[TBL] [Abstract][Full Text] [Related]
19. Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerations.
Reece PA; Stafford I; Abbott RL; Anderson C; Denham J; Freeman S; Morris RG; Gill PG; Olweny CL
J Clin Oncol; 1989 Feb; 7(2):270-5. PubMed ID: 2536803
[TBL] [Abstract][Full Text] [Related]
20. Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer.
Marth C; Tropé C; Vergote IB; Kristensen GB
Eur J Cancer; 1998 Jul; 34(8):1175-80. PubMed ID: 9849475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
